## Respiratory Disease in Poland



## Introduction

The IRC, a coalition of respiratory clinicians, patients and industry partners, aims to transform post-pandemic respiratory care and reduce mortality by a third globally by 2030 - in line with the UN Sustainable Development Goals.

The IRC is calling on governments and policy makers to establish funded national strategies, which include prevention, new models of care, ambitious measurable targets, and accountable leadership to improve lung health by focusing on:

## Better...

- 1. Prevention of respiratory diseases
- 2. Access to the right treatment at the right time
- 3. Action on reducing inequalities
- 4. Prioritisation of research, data and insight to improve care

The Polish Coalition of Healthy Lungs was established on the initiative of the Polish Lung Society in December 2022. Upon its establishment, five signatories from the pulmonary care sector have joined: the Institute of Tuberculosis and Lung Diseases, the Polish Society of Lung Diseases, the Polish Society of Paediatric Pneumonology, as well as a national consultant in the field of children's lung diseases.

The IRC welcomes the work on this initiative and is also committed to collaborating with all relevant stakeholders in promoting lung health across Poland by developing national strategies.

## Societal economic cost by disease:



Asthma
5.7zł billion



COPD **15.9zł billion** 



Interstitial Lung Disease 788.8zł million





healthy life years lost to respiratory diseases





Lower Respiratory Tract Infections 12.5zł billion



Mesothelioma
400.7zł million



Lung Cancer
42.8zł billion



Tuberculosis

1zł billion



This initiative is made possible with the contributions of the partner organisations who all support the IRC's goals: Expertise and time were provided by the European Respiratory Society, European Lung Foundation and Global Allergy and Airways Patient Platform; funding, expertise and time were contributed by AstraZeneca, Chiesi Group, GSK, Moderna, Amgen, Sanofi and Regeneron; additional funding was provided by Boehringer Ingelheim.